All In Biotech

Drug Trial Radar · NCT03551964

Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction

Cangrelor Versus Ticagrelor In Patients With Acute Myocardial Infarction Complicated With Initial Cardiogenic Shock

Last checked: Nov 20, 2026Latest source record: Apr 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 605 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

605

Actual

Start

Aug 1, 2018

Primary completion

Feb 19, 2024

Study completion Apr 1, 2025

Sponsor

Lead sponsor
Faculty Hospital Kralovske VinohradyGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Charles University, Czech Republic; Masaryk University; Ministry of Health, Czech Republic; National Institute for Metabolic and Cardiovascular Disease Research; Institute of Hematology and Blood Transfusion, Czech Republic; BioVendor LM
First posted
Jun 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, international, randomized, placebo-controlled, double-blind trial comparing intravenous cangrelor and crushed oral ticagrelor in patients with acute myocardial infarction complicated by initial cardiogenic shock (CS-AMI) and treated with primary angioplasty (PCI). The Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction (DAPT-SHOCK-AMI) trial tests the hypothesis that intravenous cangrelor is (a) more effective in terms of its rate of onset and the proportion of patients achieving effective periprocedural inhibition of ADP-induced platelet aggregation and (b) at least as effective as the recommended treatment of oral (crushed) ticagrelor in reducing major cardiovascular events in patients with initial CS-AMI indicated for primary PCI strategy.

Conditions

  • Acute Myocardial Infarction
  • Cardiogenic Shock

Interventions

  • CangrelorDrug

    Cangrelor: IV bolus 30 µg/kg (application \< 1 minute) followed immediately by continuous infusion at 4 µg/kg. Tables to calculate bolus dose in ml and infusion (in ml per hour) rate for each body weight group will be prepared in advance and will be included in the study medication kit to accelerate treatment start. * Cangrelor treatment will be discontinued after circulatory stabilization (but no earlier than 2 hours after infusion initiation) i.e. after systolic Blood Pressure (sBP) is maintained at the level \> 100 mmHg for one hour after the end of IABK and/or vasoactive treatment is discontinued, but no later than 4 hours after PCI, * 30 minutes before the end of Cangrelor infusion, administration of Ticagrelor 180 mg (crushed tablets) and then dose 90 mg every 12 hours.

  • TicagrelorDrug

    Ticagrelor: 180 mg loading dose - crushed tablets, 2 x 90 mg maintenance dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Laboratory endpointTime frame: At the end of primary percutaneous coronary intervention; Within 24 hours from randomization
  2. Primary Clinical EndpointTime frame: Within 30 days after randomization

Locations

29 sites in 5 countries. Site status is shown where the registry gives one.

  • St. Anne's University Hospital Brno

    Brno, Czechia

  • Department of Cardiology, University Hospital Brno-Bohunice

    Brno, Czechia

  • Cardiology Department, Regional Hospital

    České Budějovice, Czechia

  • University Hospital Hradec Králové

    Hradec Králové, Czechia

  • Cardiology department, Regional hospital

    Jihlava, Czechia

  • Cardiocenter, Regional Hospital

    Karlovy Vary, Czechia

  • Krajská nemocnice Liberec

    Liberec, Czechia

  • University Hospital Olomouc

    Olomouc, Czechia

  • University Hospital Ostrava

    Ostrava, Czechia

  • Department of Cardiology, Regional Hospital,

    Pardubice, Czechia

  • University Hospital Pilsen

    Pilsen, Czechia

  • General University Hospital in Prague

    Prague, Czechia

  • Institute of Clinical and Experimental Medicine

    Prague, Czechia

  • Na Homolce Hospital

    Prague, Czechia

  • Cardiocenter, Hospital Podlesi

    Třinec, Czechia

  • Masaryk Hospital

    Ústí nad Labem, Czechia

  • Regional Hospital T. Bati

    Zlín, Czechia

  • University Hospital Kralovske Vinohrady

    Prague, Please Select, Czechia

  • Département de Cardiologie, Hôpital Bichat Assistance Publique Hôpitaux de Paris

    Paris, France

  • Pitié-Salpêtrière Hospital (AP-HP)

    Paris, France

  • Heart Center Freiburg University

    Freiburg im Breisgau, Germany

  • University Medical Centre

    Mannheim, Germany

  • University Hospital Tübingen

    Tübingen, Germany

  • Collegium Medicum University Hospital No. 1

    Bydgoszcz, Poland

  • Jagiellonianan University, University Hospital Krakow

    Krakow, Poland

  • Medical University of Warsaw

    Warsaw, Poland

  • Middle-Slovak Institute of Cardiovascular Diseases

    Banská Bystrica, Slovakia

  • Center of Interventional Neuroradiology and Endovascular Treatment

    Bratislava, Slovakia

  • Cardiocentre

    Nitra, Slovakia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.